Mechanism of binding to ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies

Journal of Virology

Volumn 89, Issue 21, 2015, Pages 10982-10992

  Davidson, Edgar ^a   Bryan, Christopher ^a   Fong, Rachel ^a   Barnes, Trevor ^a   Pfaff, Jennifer ^a   Mabila, Manu ^a   Rucker, Joseph ^a   Doranz, Benjamin J ^a  

^a Integral Molecular Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13C6; MONOCLONAL ANTIBODY 13F6; MONOCLONAL ANTIBODY 1H3; MONOCLONAL ANTIBODY 2G4; MONOCLONAL ANTIBODY 4G7; MONOCLONAL ANTIBODY 6D8; MONOCLONAL ANTIBODY KZ52; MUCIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; PROTEIN BINDING; VIRUS FUSION PROTEIN; ZMAPP;

ALANINE SCANNING MUTAGENESIS; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EBOLAVIRUS; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRION; VIRUS NEUTRALIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; SERODIAGNOSIS;

ANTIBODIES, MONOCLONAL; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MUTAGENESIS; NEUTRALIZATION TESTS; PROTEIN BINDING; VIRAL FUSION PROTEINS; VIRION;

EID: 84945217199     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01490-15     Document Type: Article

References (50)

1. World Health Organization. 2015. Ebola situation report-8 July 2015. World Health Organization, Geneva, Switzerland. http://apps.who.int /ebola/current-situation/ebola-situation-report-8-july-2015.
2. Kuhn JH, Andersen KG, Bao Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Muhlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, et al. 2014. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses 6:3663-3682. http://dx .doi.org/10.3390/v6093663.
3. Leroy EM, Gonzalez JP, Baize S. 2011. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 17:964-976. http://dx.doi .org/10.1111/j.1469-0691.2011.03535.x.
4. Marzi A, Feldmann H. 2014. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 13:521-531. http://dx.doi.org/10.1586 /14760584.2014.885841.
5. Mohammadi D. 2015. Ebola vaccine trials back on track. Lancet 385:214- 215. http://dx.doi.org/10.1016/S0140-6736(15)60035-6.
6. Roddy P, Colebunders R, Jeffs B, Palma PP, Van Herp M, Borchert M. 2011. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. J Infect Dis 204(Suppl 3):S791- S795. http://dx.doi.org/10.1093/infdis/jir297.
7. Clark DV, Jahrling PB, Lawler JV. 2012. Clinical management of filovirusinfected patients. Viruses 4:1668-1686. http://dx.doi.org/10.3390/v4091668.
8. Saphire EO. 2013. An update on the use of antibodies against the filoviruses. Immunotherapy 5:1221-1233. http://dx.doi.org/10.2217/imt.13.124.
9. Wong G, Kobinger GP, Qiu X. 2014. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 10:781-790. http://dx.doi.org/10.1586/1744666X.2014.908705.
10. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109:5034-5039. http://dx.doi.org/10.1073/pnas.1200409109.
11. Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, Olinger GG. 2011. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A 108:20690-20694. http://dx .doi.org/10.1073/pnas.1108360108.
12. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 5:199ra113.
13. Olinger GG, Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad SciUSA109:18030- 18035. http://dx.doi.org/10.1073/pnas.1213709109.
14. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. 2012. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4:138ra181. http://dx.doi.org/10.1126/scitranslmed.3003876.
15. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, Takada A. 2012. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 7:e36192. http://dx.doi.org/10.1371/journal .pone.0036192.
16. Takada A, Feldmann H, Stroeher U, Bray M, Watanabe S, Ito H,McGregor M, Kawaoka Y. 2003. Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 77:1069-1074. http://dx.doi.org /10.1128/JVI.77.2.1069-1074.2003.
17. Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP. 2013. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 3:3365. http://dx.doi.org/10.1038/srep03365.
18. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther- Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47-53. http://dx.doi.org/10.1038/nature13777.
19. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Stroher U, Uyeki TM, Ribner BS, Emory Serious Communicable Diseases Unit. 2014. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371: 2402-2409. http://dx.doi.org/10.1056/NEJMoa1409838.
20. Bishop BM. 2015. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 49:196-206. http://dx.doi.org/10.1177 /1060028014561227.
21. Meyers L, Frawley T, Goss S, Kang C. 2015. Ebola virus outbreak 2014: clinical review for emergency physicians. Ann Emerg Med 65:101-108. http://dx.doi.org/10.1016/j.annemergmed.2014.10.009.
22. Roos R (ed). 2014. Experimental Ebola drug may have helped 2 US patients. CIDRAP News and Perspective Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN. http: //www.cidrap.umn.edu/news-perspective/2014/08/experimental-ebola -drug-may-have-helped-2-us-patients.
23. McCarthy M. 2014. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488. http://dx.doi.org/10.1136 /bmj.g5488.
24. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from ahuman survivor. Nature 454:177-182. http://dx.doi.org/10.1038/nature07082.
25. Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO. 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 111:17182-17187. http://dx.doi.org/10.1073/pnas.1414164111.
26. Audet J, Wong G, Wang H, Lu G, Gao GF, Kobinger G, Qiu X. 2014. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 4:6881. http://dx .doi.org/10.1038/srep06881.
27. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666. http://dx.doi.org/10.1126/science .287.5458.1664.
28. Qiu X, Alimonti JB, Melito PL, Fernando L, Stroher U, Jones SM. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol 141:218-227. http://dx.doi.org/10.1016/j.clim .2011.08.008.
29. Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ. 2013. Atomic-level functional model of dengue virus envelope protein infectivity. Proc Natl Acad Sci U S A 110: 18662-18667. http://dx.doi.org/10.1073/pnas.1310962110.
30. Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ. 2014. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol 88: 14364-14379. http://dx.doi.org/10.1128/JVI.01943-14.
31. Castelli M, Clementi N, Sautto GA, Pfaff J, Kahle KM, Barnes T, Doranz BJ, Dal Peraro M, Clementi M, Burioni R, Mancini N. 2014. HCVE2 core structures and mAbs: something is still missing. Drug Discov Today 19:1964-1970. http://dx.doi.org/10.1016/j.drudis.2014.08.011.
32. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, Rucker JB, Doranz BJ. 2009. Atomic-level mapping of antibody epitopes on a GPCR. J Am Chem Soc 131:6952-6954. http://dx .doi.org/10.1021/ja900186n.
33. Davidson E, Doranz BJ. 2014. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143:13-20. http://dx.doi.org/10.1111/imm.12323.
34. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, Wheeler DK, Gabbard JL, Hix D, Sette A, Peters B. 2015. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 43:D405-412. http://dx.doi.org/10.1093/nar/gku938.
35. Salvador B, Zhou Y, Michault A, Muench MO, Simmons G. 2009. Characterization of Chikungunya pseudotyped viruses: identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393:33-41. http://dx.doi .org/10.1016/j.virol.2009.07.013.
36. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 101:4240-4245. http://dx.doi.org/10.1073/pnas.0306446101.
37. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267. http://dx.doi .org/10.1126/science.272.5259.263.
38. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication ofhumanimmunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006/viro.1995.1016.
39. Tran EE, Simmons JA, Bartesaghi A, Shoemaker CJ, Nelson E, White JM, Subramaniam S. 2014. Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol 88:10958-10962. http://dx.doi.org/10.1128/JVI.00870-14.
40. Lee JE, Kuehne A, Abelson DM, Fusco ML, Hart MK, Saphire EO. 2008. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. J Mol Biol 375:202-216. http://dx.doi.org/10.1016/j.jmb.2007.10.017.
41. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PW, Burton DR. 1999. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73:6024-6030.
42. Bogan AA, Thorn KS. 1998. Anatomy of hot spots in protein interfaces. J Mol Biol 280:1-9. http://dx.doi.org/10.1006/jmbi.1998.1843.
43. Lo Conte L, Chothia C, Janin J. 1999. The atomic structure of proteinprotein recognition sites. J Mol Biol 285:2177-2198. http://dx.doi.org/10 .1006/jmbi.1998.2439.
44. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JL, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, et al. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369-1372. http://dx .doi.org/10.1126/science.1259657.
45. Kugelman JR, Sanchez-Lockhart M, Andersen KG, Gire S, Park DJ, Sealfon R, Lin AE, Wohl S, Sabeti PC, Kuhn JH, Palacios GF. 2015. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. mBio 6(1):e02227-14. http://dx.doi.org/10.1128/mBio.02227-14.
46. Ponomarenko J, Vaughan K, Sette A, Maurer-Stroh S. 3 November 2014. Conservancy of mAb epitopes in ebolavirus glycoproteins of previous and 2014 outbreaks. PLoS Curr 6. http://dx.doi.org/10.1371/currents .outbreaks.f1a7028a13ce1c5f0bdbb4b0cc0b919b.
47. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:1643-1645. http://dx.doi.org/10.1126/science.1110656.
48. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80:4174-4178. http://dx.doi.org/10.1128/JVI.80.8 .4174-4178.2006.
49. Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO. 2011. A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18:1424-1427. http://dx.doi.org/10 .1038/nsmb.2150.
50. Bale S, Dias JM, Fusco ML, Hashiguchi T, Wong AC, Liu T, Keuhne AI, Li S, Woods VL, Jr, Chandran K, Dye JM, Saphire EO. 2012. Structural basis for differential neutralization of ebolaviruses. Viruses 4:447-470. http://dx.doi.org/10.3390/v4040447.